This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period of 3 years, from September 1, 2023 to August 31, 2026. As a major public research institution, UC Davis frequently conducts cutting-edge biomedical research with support from federal agencies including the NIH, NSF, and DOE. This project leverages the university's expertise in cancer biology, drug discovery, and translational medicine to advance a novel therapeutic approach with the potential to improve outcomes for prostate cancer patients.
Generated 8/13/24, 8:45 AM